<DOC>
	<DOCNO>NCT00356733</DOCNO>
	<brief_summary>Erythropoietin ( EPO ) treatment patient severe cardiorenal syndrome increase cardiac performance decrease progression renal failure dampen main driving force cardiorenal syndrome part via non-erythropoietic pathway . I . Does EPO administration patient severe cardiorenal syndrome increase cardiac performance decrease progression renal disease ? II . Does EPO treatment affect main driving force cardiorenal connection , , dampen activate renin-angiotensin system ( RAS ) , attenuate increase reactive oxygen specie ( ROS ) , normalize increase sympathetic activity , decrease inflammation ? III . Does EPO treatment positively affect cell function patient cardiorenal syndrome : 1. gene expression signatures leukocytes positively influenced EPO treatment , 2. EPO shift Jak/STAT pathway less pro-inflammatory profile monocyte , 3. function number endothelial progenitor cell ( EPCs ) affect treatment EPO cardiorenal syndrome ? IV . Can direct action EPO differentiate effect hemoglobin level ?</brief_summary>
	<brief_title>Mechanisms Erythropoietin Action Cardiorenal Syndrome</brief_title>
	<detailed_description>The combination renal cardiac failure associate extraordinary cardiovascular morbidity mortality . We propose severe cardiorenal syndrome ( SCRS ) , pathophysiological condition combine cardiac renal dysfunction , amplifies progression failure individual organ . Central pathogenesis cardiorenal syndrome enhance oxidative stress , inflammation enhance activation renin-angiotensin sympathetic nervous system . Chronic renal failure accompany anemia due gradual decline erythropoietin ( EPO ) formation diseased kidney and/or EPO resistance . Recently , interest EPO increase since serf hematopoietic factor , also show increase number endothelial progenitor cell ( EPCs ) end-stage renal disease ( ESRD ) patient . Moreover , EPO involve signal via Akt support NO release may act anti-apoptotic . Some evidence support idea EPO improve cardiac renal function syndrome ; however , information available mechanism . The hypothesis present proposal EPO treatment patient severe cardiorenal syndrome increase cardiac performance decrease progression renal failure part via non-erythropoietic pathway . The question whether EPO administration patient severe cardiorenal syndrome : 1. increase cardiac performance decrease progression renal disease , 2. dampens activate RAS sympathetic nervous system , attenuates increase ROS decrease sign inflammation 3. positively influence cell function leukocyte ( assess gene expression signature ) , monocyte ( shift less pro-inflammatory Jak/Stat signal ) EPC ( number function ) . This address two-part clinical study patient combine moderate chronic renal failure heart failure ( New York Heart Association [ NYHA ] II-III ) . First , patient treat EPO 12 month , hemoglobin level keep constant initial level allow increase ; another group leave untreated . Besides cardiac renal function , RAS , SNS , ROS/NOS balance inflammatory parameter assess . Furthermore , cell function leukocytes ( gene expression signature ) , monocyte ( Jak/STAT activation ) EPCs ( number function ) study . Taken together , central proposal combine heart-kidney failure accompany relative absolute EPO dysfunction , disproportional degree renal failure treatment EPO improve cardiac performance renal function .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients moderate renal failure ( glomerular filtration rate [ GFR ] Cockroft formula 2070 ml/min ) Patients heart failure NYHA class IIIIIIV Hemoglobin ( Hb ) 6.4 7.8 mmol/L men 6.0 7.4 mmol/L woman Age &gt; 18 year , &lt; 80 year Written inform consent must obtain subject legally accept representative studyspecific procedure , include screening procedure , perform . Therapy within 1 year randomisation plan erythropoietic therapy randomisation study day 1 Known intolerance EPO administration Previously suspect confirmed neutralizing antibody recombinant human erythropoietin ( rHuEPO ) Uncontrolled hypertension ( RR &gt; 160 systolic , &gt; 100 diastolic ) Forms secondary hypertension renal hypertension Uncontrolled diabetes ( HbA1c &gt; 8.0 % ) Primary dyslipidemia Kidney transplantation Proteinuria &gt; 3.5 g/L Acute renal failure rapidly progressive glomerulonephritis Hyperparathyroidism ( parathyroid hormone [ PTH ] &gt; 40 ) Bleeding haemolysis cause anaemia Deficiency iron , folate , and/or vitamin B12 Presence chronic inflammatory disease clinically significant infection Haematologic malignancy solid tumour &lt; 5 year ago Chronic liver disease Haemoglobinopathies Alcohol and/or drug abuse Enrolment another study Child bear potential ( premenopausal woman use adequate contraceptive precaution ) Any kind disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>cardiorenal syndrome</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>Heart Failure , Congestive</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
</DOC>